LCI Industries (LCII) to pay $0.55 on Dec 1, 2017; Profile of 7 Analysts Covering Celldex Therapeutics, Inc. (CLDX)

November 15, 2017 - By Dolores Ford

LCI Industries (NYSE:LCII) is expected to pay $0.55 on Dec 1, 2017. $2.20 is the ADY. (NYSE:LCII) shareholders before Nov 16, 2017 will receive the $0.55 dividend. LCI Industries’s current price of $116.25 translates into 0.47% yield. LCI Industries’s dividend has Nov 17, 2017 as record date. Nov 6, 2017 is the announcement. The stock increased 0.56% or $0.65 during the last trading session, reaching $116.25. About shares traded. LCI Industries (NYSE:LCII) has risen 20.95% since November 15, 2016 and is uptrending. It has outperformed by 4.25% the S&P500.

Among 12 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 7 have Buy rating, 0 Sell and 5 Hold. Therefore 58% are positive. Celldex Therapeutics had 23 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Brean Capital with “Buy” on Tuesday, August 11. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, February 26. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) earned “Buy” rating by TH Capital on Tuesday, August 11. The firm earned “Hold” rating on Tuesday, August 9 by Jefferies. The firm earned “Buy” rating on Tuesday, June 6 by Cowen & Co. Cowen & Co maintained the shares of CLDX in report on Tuesday, March 8 with “Outperform” rating. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) earned “Hold” rating by Jefferies on Tuesday, March 8. The rating was maintained by Oppenheimer on Tuesday, August 11 with “Outperform”. Leerink Swann downgraded it to “Market Perform” rating and $4 target in Monday, March 7 report. As per Monday, March 7, the company rating was downgraded by Guggenheim. See Celldex Therapeutics, Inc. (NASDAQ:CLDX) latest ratings:

07/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain
12/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $9.0
31/08/2017 Broker: Jefferies Rating: Hold New Target: $3.5 Maintain
09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10.0000 Maintain
01/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10 Reinitiate
12/06/2017 Broker: Jefferies Rating: Hold New Target: $3.5000 Maintain
06/06/2017 Broker: Cowen & Co Rating: Buy Maintain

The stock increased 1.09% or $0.03 during the last trading session, reaching $2.77. About shares traded. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 20.62% since November 15, 2016 and is downtrending. It has underperformed by 37.32% the S&P500.

Celldex Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $355.51 million. The Firm is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. It currently has negative earnings. The Company’s lead drug Rintega is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Among 2 analysts covering LCI Industries LCII (NYSE:LCII), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. LCI Industries LCII had 2 analyst reports since April 12, 2017 according to SRatingsIntel. Robert W. Baird initiated LCI Industries (NYSE:LCII) on Wednesday, May 3 with “Outperform” rating.

LCI Industries, formerly Drew Industries Incorporated, through its subsidiary, Lippert Components, Inc. and its subsidiaries , supplies an array of components for the original equipment manufacturers (OEMs) of recreational vehicles (RVs) and adjacent industries. The company has market cap of $2.90 billion. The Company’s divisions include OEM Segment and Aftermarket Segment. It has a 20.74 P/E ratio. The OEM Segment makes or distributes an array of components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment and other cargo; pontoon boats; manufactured homes; modular housing, and mobile office units.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Dolores Ford




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: